Mangoceuticals, Inc. (MGRX) AI Stock Analysis

Founded in 2021 and headquartered in Dallas, Texas, Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc. with 3 employees. The company develops, markets, and distributes men's wellness products and services across the United States through its telemedicine platform, MangoRx.com. Its product lineup includes the Mango brand for erectile dysfunction and the Grow brand for hair loss solutions. Mangoceuticals also maintains a strategic marketing agreement with Marius Pharmaceuticals, LLC to market and distribute KYZATREX, an oral testosterone replacement therapy product, under its PRIME program.

Mangoceuticals generated $8,939 in revenue in FY2022 before expanding to $731,493 in FY2023, reflecting revenue growth of 8083.2%. However, annual revenue subsequently contracted, falling 15.8% to $615,873 in FY2024 and decreasing 26.0% to $456,021 in FY2025. Despite this recent slowdown, three-year revenue CAGR from FY2022 to FY2025 was 270.9%. Gross margin stood at 54.3% in FY2022, 59.0% in FY2023, 61.7% in FY2024, and 54.9% in FY2025. Net income was -$2.0M in FY2022, -$9.2M in FY2023, -$8.7M in FY2024, and -$20.6M in FY2025, yielding a FY2025 net margin of -4526.9% and an EPS of -$2.71. In the latest quarter ended June 30, 2026, quarterly revenue fell 59.1% year-over-year, bringing trailing twelve-month revenue to $315,227.

As of June 30, 2026, Mangoceuticals held $228,688 in cash and short-term investments against total debt of $324,151, resulting in net debt of $95,463. Total assets were $14.2M and shareholders' equity was $12.5M, giving a debt-to-equity ratio of 0.03. However, liquidity remains constrained with a current ratio of 0.18. In FY2025, operating cash flow was -$5.9M and free cash flow was -$5.9M, while capital expenditures were $5. Additionally, the company's share count increased 1615.9% over five years.

At a last close of $0.29 on October 16, 2026, Mangoceuticals carried a market capitalization of $6.4M and an enterprise value of $9.9M. The stock trades at a price-to-sales multiple of 20.4x and an EV-to-revenue ratio of 31.4x, well above the median of its US-listed Healthcare peers, which have a price-to-sales multiple of 4.1x. Its price-to-book ratio is 0.8x. Over the past year, the stock fell 88.2%, underperforming the S&P 500 benchmark return of 16.8%.

No Wall Street analyst recommendations, consensus price targets, or earnings estimates are available for Mangoceuticals. Historical earnings beat-and-miss track records are also unrecorded. The company's next scheduled earnings date is November 13, 2026. Trading at $0.29 as of October 16, 2026, the equity exhibits heightened volatility with a beta of 1.98 and trades 33.3% below its 200-day moving average.

This page is an AI-written research summary of Mangoceuticals, Inc. (MGRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MGRX income statement, MGRX balance sheet, MGRX key metrics, MGRX chart. See the MGRX stock overview for the latest quote and news.